Table 3 Summary of data regarding the prognostic role of PD-L1 in treatment efficacy of EGFR-TKIs.
Author | Year | Patient number | PD-L1 antibody | Outcome associated with high PD-L1 expression |
|---|---|---|---|---|
D’Incecco et al.42 | 2015 | 95 | Ab58810 | Better RR and longer TTP |
Lin et al.43 | 2015 | 56 | Ab58810 | Better DCR and longer PFS |
Tang et al.41 | 2015 | 64 | E1L3N | No association |
Soo et al.11 | 2017 | 90 | SP142 | Shorter PFS |
Yoneshima et al.14 | 2018 | 71 | Dako 22C3 | Shorter PFS |
Su et al.12 | 2018 | 101 | SP142 | Poor RR, shorter PFS, higher primary resistance rate |
Hsu et al.8 | 2019 | 123 | SP263 | Shorter PFS, higher primary resistance rate |
Matsumoto et al.10 | 2019 | 52 | 28-8 | Shorter PFS |
D7U8C | ||||
Yang et al.13 | 2020 | 153 | Dako 22C3 | Poor RR, shorter PFS, higher primary resistance rate |
Yoon et al.15 | 2020 | 131 | Dako 22C3 | Poor RR and shorter PFS |
Kim et al.44 | 2020 | 69 | SP142 | No association |
SP263 | ||||
Dako 22C3 | ||||
Chang et al.19 | 2021 | 114 | Dako 22C3 | No association |
Liu et al.9 | 2021 | 186 | SP263 | Shorter PFS |
Present study | 2022 | 157 | Dako 22C3 | Shorter PFS |
Associated with BIM expression |
